Over a hundred active companies.
One of the avenues of tremendous therapeutic potential is tissue engineering and cell therapy. Admittedly, these two disciplines cover a great deal of ground and even individually are represented by many different scientific methods. Still, their successes draw from common scientific threads, which have seen many advances in yielding potential applications that have converted to successful clinical applications. So many therapeutic benefits are to varying degrees already within our grasp, or about to be so. (Contrast this with gene therapy, a discipline of enormous potential, but still disappointingly distant.) Tissue engineered skin, urinary bladders and more structures are offering therapeutic solutions where previously there was either none or just greatly compromised quality of life. Medicine is increasing developing along lines that leverage the latent power of the human body to regenerate and heal.
MedMarket Diligence is undertaking a review of tissue engineering and cell therapy companies. When we last provided an analysis of the status of technologies and applications, back in 2005, we highlighted a striking number of companies, a good share of which were more academic than commercial. But now, even with our more critical view yielding a smaller number of active companies, we find a very strong industry, with many approvals, pending approvals and technologies with outstanding near-term potential.
Below, find a list of our preliminarily identified active tissue engineering and cell therapy companies:
3DM Inc., Aastrom Bioscience Inc., Acorda Therapeutics Inc., Advanced Cell Technology, Inc., Advanced Medical Solutions PLC, AdvanSource Biomaterials, Aeolus Pharmaceuticals, Alexion Pharmaceuticals, Angiotech Pharmaceuticals, Inc., Ariad Pharmaceuticals Inc., Avax Technologies Inc., Avita Medical Limited, Baxter International Inc., BD Biosciences, BeFutur Biotechnologies, Biocomposites, Biocoral Inc., Bioheart Inc., BioHybrid Technologies, BioLife Solutions Inc., Biomet, Inc., BioMimetic Pharmaceuticals, Bio Nova International, BioSyntech, BioTissue Technologies GmbH, Bio-Vascular Inc., Bose Corporation, Boston Scientific Corporation, BrainStorm Cell Therapeutics, Inc., Breonics Perfusion Technologies, Inc., BTG International Ltd, California Stem Cells Inc., Capstone Therapeutics, Celgene Corporation, CellECT Bio Inc., Cell Genesys Inc., CellSeed, Inc., CellTran Ltd., Cerco Medical, Chiron, Chromos Molecular Systems, Inc., co.don AG, ConMed Linvatec Biomaterials, Inc., Cook Group, CorCell, Inc., Cryo-Cell International, Inc., CryoLife, Inc., Curis Inc., Cyclacel Pharmaceuticals, Inc., Cytograft Tissue Engineering, Cytomatrix LLC, Cytori Therapeutics Inc., ES Cell International, Exactech, Inc., Excorp Medical, Inc., FibroGen, Inc., Fidia Advanced Biopolymers, Forticell Bioscience, Inc., Gamida Cell Ltd., Garnet BioTherapeutics, Genta, Inc., Genetix Ltd, Genetix Pharmaceuticals Inc., GenVec, Inc., Genzyme Corporation, Genzyme Biosurgery, Genzyme Oncology, Geron Corporation, HemoCleanse, Inc., HepaLife Technologies, Inc., Hospira, Inion Ltd, Innogenetics, InnovaCell Biotechnologie GmbH, Integra LifeSciences Inc., Interface Biologics Inc., ISTO Technologies Inc., Ixion Biotechnology Inc., Johnson & Johnson Inc. (Ethicon, DePuy), Kensey Nash, Keratec, LifebankUSA, LifeCell Inc., LifeStem Inc. (Calba Tech, Inc.), Living Cell Technologies Ltd., Lonza Group Ltd., MacroPore Biosurgery Inc., MaxCyte, Medtronic, MG Biotherapeutics, LLC, MicroIslet Inc., Musculoskeletal Transplant Foundation, Natural Implant, NeuroGeneration, Inc., NeuroNova AB, Neurotech, Novartis International AG, Novocell Inc., Novo Nordisk A/B, OncoMed Pharmaceuticals, Organogenesis Inc., Ortho Biotech, Orthovita, OSI Pharmaceuticals, Osiris Therapeutics Inc., Osteotech, Pioneer Surgical Technologies, Polyganics BV, Poly-Med, Inc., Protein Polymer Technologies Inc., Progenitor Cell Therapy Inc., ProNeuron Biotechnologies, Inc., ReGen Biologics Inc., RTI Biologics, Inc., ReInnervate Ltd., ReNeuron Ltd., Revivicor, Inc., Sanofi-Aventis, Sciperio Inc., Selective Genetics, Sernova Corp., Smith & Nephew Ltd., Stem Cell Pharma Inc., StemCells Inc., Stem Cell Sciences UK Ltd., StemCell Technologies Inc., Stryker Corporation, Synovis Life Technologies, Inc., Targeted Genetics Corporation, TEI Biosciences Inc., Tepha Inc., Theratechnologies Inc., TiGenix N.V., Tissuemed Ltd., Titan Pharmaceuticals Inc., Tolerrx, Inc., Transition Therapeutics Inc, TriStem Corporation, Vesta Therapeutics, ViaCell, Inc., Vital Therapies, Inc., Vitrolife AB.
—–
The MedMarket Diligence report is pending a preliminary publication date.
Post a Comment